Translation of tumor microenvironment imaging studies into routine clinical human applications. Currently funded through NIH/NCI RO1 Whole-Body PET/CT Assessment of Tumor Perfusion Using Generator-Produced 5R01CA140299-02. This project evaluates a non-invasive PET method for assessment of tumor perfusion using generator-produced copper-62. The proposed method will be suitable for implementation at any clinical PET center in the U.S., complementing current clinical whole-body PET F-18-FDG studies to assess tumor metabolism. The project's clinical focus is patients with head-and-neck cancer, where literature evidence indicates that tumor perfusion measurements can be predictive of response to therapy. Patients with localized or locally advanced head and neck cancer, who receive concurrent chemo-radiation therapy, receive the investigational Cu-62-ETS radiopharmaceutical for whole-body; PET/CT imaging to assess tumor perfusion. The Cu-62-ETS imaging occurs immediately prior to scheduled standard 18-F-FDG baseline imaging and three months post-therapy. Clinical PET/CT with F-18-FDG is performed at both time intervals. Patients are also imaged using O-15-water to provide an independent reference measure of tumor perfusion. The Cu-62-ETS tumor perfusion results are quantified using an image-derived arterial input function.We have also expanded the scope of the RO1 to now include patients with advanced stage renal cell cancer with ITRAC pilot funding. This project involves Drs. Logan, Mark Green and Gary Hutchins. Patients are evaluated at baseline and after a course of Sutent to assess changes in the perfusion of their metastatic lesions as a means of evaluating response to therapy and prognosis.
Fellowship - St. Louis Universtiy School of Medicine, St. Louis, MO 1970-1971
Residency - St. Louis University School of Medicine, St. Louis, MO 1969-1970
Internship - St. Louis University School of Medicine, St. Louis, MO 1968-1969
M.D. - St. Louis University School of Medicine, St.Louis, MO 1968